Skip to main content
Top
Published in: Clinical Research in Cardiology 12/2011

Open Access 01-12-2011 | Review

Sympatho-renal axis in chronic disease

Authors: Paul A. Sobotka, Felix Mahfoud, Markus P. Schlaich, Uta C. Hoppe, Michael Böhm, Henry Krum

Published in: Clinical Research in Cardiology | Issue 12/2011

Login to get access

Abstract

Essential hypertension, insulin resistance, heart failure, congestion, diuretic resistance, and functional renal disease are all characterized by excessive central sympathetic drive. The contribution of the kidney’s somatic afferent nerves, as an underlying cause of elevated central sympathetic drive, and the consequences of excessive efferent sympathetic signals to the kidney itself, as well as other organs, identify the renal sympathetic nerves as a uniquely logical therapeutic target for diseases linked by excessive central sympathetic drive. Clinical studies of renal denervation in patients with resistant hypertension using an endovascular radiofrequency ablation methodology have exposed the sympathetic link between these conditions. Renal denervation could be expected to simultaneously affect blood pressure, insulin resistance, sleep disorders, congestion in heart failure, cardiorenal syndrome and diuretic resistance. The striking epidemiologic evidence for coexistence of these disorders suggests common causal pathways. Chronic activation of the sympathetic nervous system has been associated with components of the metabolic syndrome, such as blood pressure elevation, obesity, dyslipidemia, and impaired fasting glucose with hyperinsulinemia. Over 50% of patients with essential hypertension are hyperinsulinemic, regardless of whether they are untreated or in a stable program of treatment. Insulin resistance is related to sympathetic drive via a bidirectional mechanism. In this manuscript, we review the data that suggests that selective impairment of renal somatic afferent and sympathetic efferent nerves in patients with resistant hypertension both reduces markers of central sympathetic drive and favorably impacts diseases linked through central sympathetics—insulin resistance, heart failure, congestion, diuretic resistance, and cardiorenal disorders.
Literature
1.
go back to reference Esler M (2010) The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol 108:227–237PubMedCrossRef Esler M (2010) The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol 108:227–237PubMedCrossRef
2.
go back to reference DiBona GF (2005) Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 289:R633–R641PubMedCrossRef DiBona GF (2005) Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 289:R633–R641PubMedCrossRef
3.
go back to reference Esler M, Lambert G, Jennings G (1989) Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A 11(Suppl 1):75–89PubMedCrossRef Esler M, Lambert G, Jennings G (1989) Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A 11(Suppl 1):75–89PubMedCrossRef
4.
go back to reference Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA (2003) Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108:3097–3101PubMedCrossRef Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA (2003) Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108:3097–3101PubMedCrossRef
5.
go back to reference DiBona GF, Sawin LL (1991) Role of renal nerves in sodium retention of cirrhosis and congestive heart failure. Am J Physiol 260:R298–R305PubMed DiBona GF, Sawin LL (1991) Role of renal nerves in sodium retention of cirrhosis and congestive heart failure. Am J Physiol 260:R298–R305PubMed
6.
go back to reference Mahfoud F, Böhm M (2010) Interventional renal sympathetic denervation—a new approach for patients with resistant hypertension. Dtsch Med Wochenschr 135:2422–2425PubMedCrossRef Mahfoud F, Böhm M (2010) Interventional renal sympathetic denervation—a new approach for patients with resistant hypertension. Dtsch Med Wochenschr 135:2422–2425PubMedCrossRef
7.
go back to reference Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC (2003) Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertension 21:1709–1717CrossRef Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC (2003) Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertension 21:1709–1717CrossRef
8.
go back to reference Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD (2004) Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 43:169–175PubMedCrossRef Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD (2004) Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 43:169–175PubMedCrossRef
9.
go back to reference Campese VM (1997) Neurogenic factors and hypertension in chronic renal failure. J Nephrol 10:184–187PubMed Campese VM (1997) Neurogenic factors and hypertension in chronic renal failure. J Nephrol 10:184–187PubMed
10.
go back to reference Ye S, Zhong H, Yanamadala V, Campese VM (2002) Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 15:717–724PubMedCrossRef Ye S, Zhong H, Yanamadala V, Campese VM (2002) Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 15:717–724PubMedCrossRef
11.
go back to reference Joles JA, Koomans HA (2004) Causes and consequences of increased sympathetic activity in renal disease. Hypertension 43:699–706PubMedCrossRef Joles JA, Koomans HA (2004) Causes and consequences of increased sympathetic activity in renal disease. Hypertension 43:699–706PubMedCrossRef
12.
go back to reference Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH (2002) Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974–1979PubMedCrossRef Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH (2002) Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974–1979PubMedCrossRef
13.
go back to reference Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M (2011) Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 123:209–215PubMedCrossRef Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M (2011) Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 123:209–215PubMedCrossRef
14.
go back to reference Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361:932–934PubMedCrossRef Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361:932–934PubMedCrossRef
15.
go back to reference Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281PubMedCrossRef Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281PubMedCrossRef
16.
go back to reference Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity htn-2 trial): a randomised controlled trial. Lancet 376:1903–1909PubMedCrossRef Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity htn-2 trial): a randomised controlled trial. Lancet 376:1903–1909PubMedCrossRef
17.
go back to reference Doumas M, Douma S (2010) Renal sympathetic denervation: the jury is still out. Lancet 376:1878–1880PubMedCrossRef Doumas M, Douma S (2010) Renal sympathetic denervation: the jury is still out. Lancet 376:1878–1880PubMedCrossRef
18.
go back to reference Fitzgerald PJ (2009) Is elevated noradrenaline an aetiological factor in a number of diseases? Auton Autacoid Pharmacol 29:143–156PubMedCrossRef Fitzgerald PJ (2009) Is elevated noradrenaline an aetiological factor in a number of diseases? Auton Autacoid Pharmacol 29:143–156PubMedCrossRef
19.
go back to reference Barajas L (1978) Innervation of the renal cortex. Fed Proc 37:1192–1201PubMed Barajas L (1978) Innervation of the renal cortex. Fed Proc 37:1192–1201PubMed
21.
go back to reference Esler M, Jennings G, Biviano B, Lambert G, Hasking G (1986) Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol 8(Suppl 5):S39–S43PubMedCrossRef Esler M, Jennings G, Biviano B, Lambert G, Hasking G (1986) Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol 8(Suppl 5):S39–S43PubMedCrossRef
22.
go back to reference Esler M, Jennings G, Lambert G (1989) Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens 2:140S–146SPubMed Esler M, Jennings G, Lambert G (1989) Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens 2:140S–146SPubMed
23.
go back to reference Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI (1986) Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73:615–621PubMedCrossRef Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI (1986) Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73:615–621PubMedCrossRef
24.
go back to reference Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527–1539PubMedCrossRef Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527–1539PubMedCrossRef
25.
go back to reference Aggarwal A, Esler MD, Morris MJ, Lambert G, Kaye DM (2003) Regional sympathetic effects of low-dose clonidine in heart failure. Hypertension 41:553–557PubMedCrossRef Aggarwal A, Esler MD, Morris MJ, Lambert G, Kaye DM (2003) Regional sympathetic effects of low-dose clonidine in heart failure. Hypertension 41:553–557PubMedCrossRef
26.
go back to reference Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B (2005) Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 26:906–913PubMedCrossRef Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B (2005) Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 26:906–913PubMedCrossRef
27.
go back to reference Dickstein K (2008) Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. Reply. Eur Heart J 29:2388–2442 Dickstein K (2008) Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. Reply. Eur Heart J 29:2388–2442
28.
go back to reference Gheorghiade M, Colucci WS, Swedberg K (2003) Beta-blockers in chronic heart failure. Circulation 107:1570–1575PubMedCrossRef Gheorghiade M, Colucci WS, Swedberg K (2003) Beta-blockers in chronic heart failure. Circulation 107:1570–1575PubMedCrossRef
29.
go back to reference Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS (2002) Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354–1359PubMedCrossRef Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS (2002) Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354–1359PubMedCrossRef
30.
go back to reference Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E (2001) Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? JASN 12:602–605PubMed Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E (2001) Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? JASN 12:602–605PubMed
31.
go back to reference Hausberg M, Tokmak F, Pavenstadt H, Kramer BK, Rump LC (2010) Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J Hypertension 28:1920–1927CrossRef Hausberg M, Tokmak F, Pavenstadt H, Kramer BK, Rump LC (2010) Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J Hypertension 28:1920–1927CrossRef
32.
go back to reference Katholi RE (1985) Renal nerves and hypertension: an update. Fed Proc 44:2846–2850PubMed Katholi RE (1985) Renal nerves and hypertension: an update. Fed Proc 44:2846–2850PubMed
33.
go back to reference O’Hagan KP, Thomas GD, Zambraski EJ (1990) Renal denervation decreases blood pressure in doca-treated miniature swine with established hypertension. Am J Hypertens 3:62–64PubMed O’Hagan KP, Thomas GD, Zambraski EJ (1990) Renal denervation decreases blood pressure in doca-treated miniature swine with established hypertension. Am J Hypertens 3:62–64PubMed
34.
go back to reference Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP (1995) Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 25:893–897PubMed Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP (1995) Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 25:893–897PubMed
35.
go back to reference Norman RA Jr, Murphy WR, Dzielak DJ, Khraibi AA, Carroll RG (1984) Role of the renal nerves in one-kidney, one clip hypertension in rats. Hypertension 6:622–626PubMed Norman RA Jr, Murphy WR, Dzielak DJ, Khraibi AA, Carroll RG (1984) Role of the renal nerves in one-kidney, one clip hypertension in rats. Hypertension 6:622–626PubMed
36.
go back to reference Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van Zwieten PA (2007) The sympathetic nervous system and the metabolic syndrome. J Hypertension 25:909–920CrossRef Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van Zwieten PA (2007) The sympathetic nervous system and the metabolic syndrome. J Hypertension 25:909–920CrossRef
37.
go back to reference Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association professional education committee of the council for high blood pressure research. Circulation 117:e510–e526PubMedCrossRef Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association professional education committee of the council for high blood pressure research. Circulation 117:e510–e526PubMedCrossRef
38.
go back to reference Yumino D, Redolfi S, Ruttanaumpawan P, Su MC, Smith S, Newton GE, Mak S, Bradley TD (2010) Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation 121:1598–1605PubMedCrossRef Yumino D, Redolfi S, Ruttanaumpawan P, Su MC, Smith S, Newton GE, Mak S, Bradley TD (2010) Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation 121:1598–1605PubMedCrossRef
39.
go back to reference Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, Michalowska I, Kabat M, Warchol E, Januszewicz M, Narkiewicz K, Somers V, Sobotka P, Januszewicz A (2011) Effects of renal sympathetic denervation on blood pressure in patients with resistant hypertension and sleep apnea—a preliminary report. TRenD Meeting 2011, Frankfurt, Germany Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, Michalowska I, Kabat M, Warchol E, Januszewicz M, Narkiewicz K, Somers V, Sobotka P, Januszewicz A (2011) Effects of renal sympathetic denervation on blood pressure in patients with resistant hypertension and sleep apnea—a preliminary report. TRenD Meeting 2011, Frankfurt, Germany
40.
go back to reference Grassi G, Facchini A, Trevano FQ, Dell’Oro R, Arenare F, Tana F, Bolla G, Monzani A, Robuschi M, Mancia G (2005) Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 46:321–325PubMedCrossRef Grassi G, Facchini A, Trevano FQ, Dell’Oro R, Arenare F, Tana F, Bolla G, Monzani A, Robuschi M, Mancia G (2005) Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 46:321–325PubMedCrossRef
41.
go back to reference Lima NK, Abbasi F, Lamendola C, Reaven GM (2009) Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens 22:106–111PubMedCrossRef Lima NK, Abbasi F, Lamendola C, Reaven GM (2009) Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens 22:106–111PubMedCrossRef
42.
go back to reference Julius S, Gudbrandsson T, Jamerson K, Tariq Shahab S, Andersson O (1991) The hemodynamic link between insulin resistance and hypertension. J Hypertension 9:983–986CrossRef Julius S, Gudbrandsson T, Jamerson K, Tariq Shahab S, Andersson O (1991) The hemodynamic link between insulin resistance and hypertension. J Hypertension 9:983–986CrossRef
43.
go back to reference Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Bohm M (2011) Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123:1940–1946PubMedCrossRef Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Bohm M (2011) Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123:1940–1946PubMedCrossRef
44.
go back to reference Schlaich MP, Straznicky N, Grima M, Ika-Sari C, Dawood T, Mahfoud F, Lambert E, Chopra R, Socratous F, Hennebry S, Eikelis N, Bohm M, Krum H, Lambert G, Esler MD, Sobotka PA (2011) Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertension 29:991–996CrossRef Schlaich MP, Straznicky N, Grima M, Ika-Sari C, Dawood T, Mahfoud F, Lambert E, Chopra R, Socratous F, Hennebry S, Eikelis N, Bohm M, Krum H, Lambert G, Esler MD, Sobotka PA (2011) Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertension 29:991–996CrossRef
45.
go back to reference Luippold G, Beilharz M, Muhlbauer B (2004) Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 19:342–347PubMedCrossRef Luippold G, Beilharz M, Muhlbauer B (2004) Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 19:342–347PubMedCrossRef
46.
go back to reference Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819–823PubMedCrossRef Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819–823PubMedCrossRef
47.
go back to reference Floras JS (2009) Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 54:375–385PubMedCrossRef Floras JS (2009) Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 54:375–385PubMedCrossRef
48.
go back to reference Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol heart failure study group. N Engl J Med 334:1349–1355PubMedCrossRef Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol heart failure study group. N Engl J Med 334:1349–1355PubMedCrossRef
49.
go back to reference Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (solvd). Circulation 82:1724–1729PubMedCrossRef Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (solvd). Circulation 82:1724–1729PubMedCrossRef
50.
go back to reference Jessup M, Costanzo MR (2009) The cardiorenal syndrome: do we need a change of strategy or a change of tactics? J Am Coll Cardiol 53:597–599PubMedCrossRef Jessup M, Costanzo MR (2009) The cardiorenal syndrome: do we need a change of strategy or a change of tactics? J Am Coll Cardiol 53:597–599PubMedCrossRef
51.
go back to reference Schrier RW (1990) Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Internal Med 113:155–159 Schrier RW (1990) Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Internal Med 113:155–159
52.
go back to reference Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen NJ (1986) Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J (Clin Res Ed) 292:1351–1353CrossRef Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen NJ (1986) Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J (Clin Res Ed) 292:1351–1353CrossRef
53.
go back to reference Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 120:2177–2187PubMedCrossRef Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 120:2177–2187PubMedCrossRef
54.
go back to reference Villarreal D, Freeman RH, Johnson RA, Simmons JC (1994) Effects of renal denervation on postprandial sodium excretion in experimental heart failure. Am J Physiol 266:R1599–R1604PubMed Villarreal D, Freeman RH, Johnson RA, Simmons JC (1994) Effects of renal denervation on postprandial sodium excretion in experimental heart failure. Am J Physiol 266:R1599–R1604PubMed
55.
go back to reference Nozawa T, Igawa A, Fujii N, Kato B, Yoshida N, Asanoi H, Inoue H (2002) Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats. Heart Vessels 16:51–56PubMedCrossRef Nozawa T, Igawa A, Fujii N, Kato B, Yoshida N, Asanoi H, Inoue H (2002) Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats. Heart Vessels 16:51–56PubMedCrossRef
56.
go back to reference Masaki H, Imaizumi T, Harasawa Y, Takeshita A (1994) Dynamic arterial baroreflex in rabbits with heart failure induced by rapid pacing. Am J Physiol 267:H92–H99PubMed Masaki H, Imaizumi T, Harasawa Y, Takeshita A (1994) Dynamic arterial baroreflex in rabbits with heart failure induced by rapid pacing. Am J Physiol 267:H92–H99PubMed
57.
go back to reference Clayton SC, Haack KK, Zucker IH (2011) Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol 300:F31–F39PubMedCrossRef Clayton SC, Haack KK, Zucker IH (2011) Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol 300:F31–F39PubMedCrossRef
58.
go back to reference Steinback CD, Salzer D, Medeiros PJ, Kowalchuk J, Shoemaker JK (2009) Hypercapnic vs. Hypoxic control of cardiovascular, cardiovagal, and sympathetic function. Am J Physiol Regul Integr Comp Physiol 296:R402–R410PubMedCrossRef Steinback CD, Salzer D, Medeiros PJ, Kowalchuk J, Shoemaker JK (2009) Hypercapnic vs. Hypoxic control of cardiovascular, cardiovagal, and sympathetic function. Am J Physiol Regul Integr Comp Physiol 296:R402–R410PubMedCrossRef
59.
go back to reference Chowdhury M, Adams S, Whellan DJ (2010) Sleep-disordered breathing and heart failure: focus on obstructive sleep apnea and treatment with continuous positive airway pressure. J Card Fail 16:164–174PubMedCrossRef Chowdhury M, Adams S, Whellan DJ (2010) Sleep-disordered breathing and heart failure: focus on obstructive sleep apnea and treatment with continuous positive airway pressure. J Card Fail 16:164–174PubMedCrossRef
60.
go back to reference Holzer-Richling N, Holzer M, Herkner H, Riedmuller E, Havel C, Kaff A, Malzer R, Schreiber W (2011) Randomized placebo controlled trial of furosemide on subjective perception of dyspnoea in patients with pulmonary oedema because of hypertensive crisis. Eur J Clin Invest 41:627–634 Holzer-Richling N, Holzer M, Herkner H, Riedmuller E, Havel C, Kaff A, Malzer R, Schreiber W (2011) Randomized placebo controlled trial of furosemide on subjective perception of dyspnoea in patients with pulmonary oedema because of hypertensive crisis. Eur J Clin Invest 41:627–634
61.
go back to reference Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O’Connor CM, Califf RM, Adams KF Jr (2007) Relation between dose of loop diuretics and outcomes in a heart failure population: results of the escape trial. Eur J Heart Fail 9:1064–1069PubMedCrossRef Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O’Connor CM, Califf RM, Adams KF Jr (2007) Relation between dose of loop diuretics and outcomes in a heart failure population: results of the escape trial. Eur J Heart Fail 9:1064–1069PubMedCrossRef
62.
go back to reference Smilde TD, Damman K, van der Harst P, Navis G, Westenbrink BD, Voors AA, Boomsma F, van Veldhuisen DJ, Hillege HL (2009) Differential associations between renal function and “modifiable” risk factors in patients with chronic heart failure. Clin Res Card 98:121–129CrossRef Smilde TD, Damman K, van der Harst P, Navis G, Westenbrink BD, Voors AA, Boomsma F, van Veldhuisen DJ, Hillege HL (2009) Differential associations between renal function and “modifiable” risk factors in patients with chronic heart failure. Clin Res Card 98:121–129CrossRef
63.
go back to reference Ellison DH (2001) Diuretic therapy and resistance in congestive heart failure. Cardiology 96:132–143PubMedCrossRef Ellison DH (2001) Diuretic therapy and resistance in congestive heart failure. Cardiology 96:132–143PubMedCrossRef
64.
65.
go back to reference Del Pace S, Parodi G, Bellandi B, Zampini L, Venditti F, Ardito M, Antoniucci D, Gensini GF (2011) Anxiety trait in patients with stress-induced cardiomyopathy: a case-control study. Clin Res Card 100:523–529CrossRef Del Pace S, Parodi G, Bellandi B, Zampini L, Venditti F, Ardito M, Antoniucci D, Gensini GF (2011) Anxiety trait in patients with stress-induced cardiomyopathy: a case-control study. Clin Res Card 100:523–529CrossRef
66.
go back to reference Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Ivabradine and outcomes in chronic heart failure (shift): a randomised placebo-controlled study. Lancet 376:875–885PubMedCrossRef Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Ivabradine and outcomes in chronic heart failure (shift): a randomised placebo-controlled study. Lancet 376:875–885PubMedCrossRef
67.
go back to reference Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Heart rate as a risk factor in chronic heart failure (shift): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886–894PubMedCrossRef Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Heart rate as a risk factor in chronic heart failure (shift): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886–894PubMedCrossRef
68.
go back to reference Moss AJ, Schwartz PJ, Crampton RS, Locati E, Carleen E (1985) The long qt syndrome: a prospective international study. Circulation 71:17–21PubMedCrossRef Moss AJ, Schwartz PJ, Crampton RS, Locati E, Carleen E (1985) The long qt syndrome: a prospective international study. Circulation 71:17–21PubMedCrossRef
69.
go back to reference Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J (2010) Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55:619–626PubMedCrossRef Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J (2010) Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55:619–626PubMedCrossRef
Metadata
Title
Sympatho-renal axis in chronic disease
Authors
Paul A. Sobotka
Felix Mahfoud
Markus P. Schlaich
Uta C. Hoppe
Michael Böhm
Henry Krum
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Clinical Research in Cardiology / Issue 12/2011
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-011-0335-y

Other articles of this Issue 12/2011

Clinical Research in Cardiology 12/2011 Go to the issue